Cephalothin Sodium
FDA-approved product (injectable, injection), marketed as Cephalothin, Cephalothin Sodium, Cephalothin Sodium W/ Dextrose In Plastic Container and 4 more.
- Registered studies
- 1
- Lab records
- 29
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- First-generation cephalosporins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DB03
Repurposing investigation
Cephalothin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA91.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli6.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 4 of 4 lab records
- E. coli: measured active in 0 of 1 lab record
- K. pneumoniae: measured active in 2 of 24 lab records
Show the 29 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cephalothin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ziprasidone MesylateExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 5 more50.3% AI-predicted activityagainst E. coli50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm50.2% AI-predicted activityagainst E. coli50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more50.2% AI-predicted activityagainst E. coli50+ registered studies
- GefitinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.1% AI-predicted activityagainst E. coli50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma50.0% AI-predicted activityagainst E. coli40 registered studies
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more50.0% AI-predicted activityagainst E. coli50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis49.8% AI-predicted activityagainst E. coli28 registered studies
- IrbesartanExisting use: Cardiovascular disease, Chronic kidney disease, Chronic renal failure syndrome and 3 more49.8% AI-predicted activityagainst E. coli50+ registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis49.8% AI-predicted activityagainst E. coli2 registered studies
- Fosdenopterin HydrobromideExisting use: Inborn metal metabolism disorder, Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A49.7% AI-predicted activityagainst E. coliNo documented evidence found
- NevirapineExisting use: HIV infection, HIV-1 infection, Viral disease49.7% AI-predicted activityagainst E. coli50+ registered studies
- Lapatinib DitosylateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more49.6% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Undisplaced Femoral Neck Fractures in the Elderly: A Trial Comparing Internal Fixation to Hemiarthroplasty
NCT01770769 · start 2012-02-06
Registered record
- Registry ID
- NCT01770769
- Conditions
- Femoral Neck Fractures
- Interventions
- Hemi - arthroplasty; internal fixation
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2012-02-06
- Completion
- 2020-02-06
- Enrolment
- 220
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFemoral Neck FracturesInterventionHemi - arthroplasty; internal fixationPhaseNot applicableRegistry statusUnknown